ArticleCaspian journal of internal medicine2025
Association of MicroRNA-103 expression with type 2 diabetes mellitus.
Article in Caspian journal of internal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- From In Silico to Clinic: Harnessing Noncoding RNAs for Diabetes Research and Therapy, a Step toward ncRNA Precision.ACS pharmacology & translational science · 2026Review
- Deregulated miR-487b-3p in Patients with Non-Alcoholic Fatty Liver Disease and Its Regulatory Effect on Insulin Resistance.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2026Article
- Exploring the Evidence for Personalized Pharmacotherapy in Type 2 Diabetes-A Systematic Review.Journal of personalized medicine · 2025Review
- MicroRNA- 103 as a novel potential biomarker of poor prognosis and durg resistance in solid tumours.Discover oncology · 2025Article
- The Cross Talk of MicroRNAs and SATB2 Signaling Pathway in Osteogenesis in the Context of Dental Implants.International journal of molecular and cellular medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Type 2 diabetes mellitus (T2DM), the most prevalent metabolic disorder worldwide, has genetic, epigenetic, and environmental contributors. Among them, circulating microRNAs (miRNAs/miRs) have attracted considerable attention. This study aimed to investigate the regulatory role of miR-103 in T2DM development. Methods: The miR-103 expression was evaluated in 33 participants with T2DM compared with 38 healthy controls using quantitative real-time polymerase chain reaction (q-RT PCR). Fasting blood glucose (FBS), fasting insulin (Fin), hemoglobin A1c (HbA1c), triglycerides (TG), and cholesterol (Chol) were also determined in serum. Basal insulin resistance and sensitivity were determined using the homeostasis model assessment insulin resistance (HOMA-IR) and quantitative insulin sensitivity check index (QUICKI), respectively. Results: There was a significant decrease in miR-103 levels in patients with T2DM (p<0.002). Serum miR-103 expression levels showed a strong correlation with age, FBS, HbA1c, TG, Chol levels, and HOMA-IR and QUICKI indices. Conclusion: The downregulation of miR-103 in T2DM patients suggests the diagnostic potential of miR-103 evaluation in conjunction with other diagnostic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.